Brief: Bioarctic And Eisai Says Sign Research Evaluation Agreement Regarding BAN2802
20/04/2024 08:42
April 20 (Reuters) - BioArctic AB BIOAb.ST :
* BIOARCTIC AND EISAI SIGN RESEARCH EVALUATION AGREEMENT
REGARDING
BAN2802
* BIOARCTIC - EISAI WILL EVALUATE DATA GENERATED AND DECIDE
IF
THEY CHOSE TO EXERCISE AN OPTION TO LICENSE BAN2802 FOR
TREATMENT OF ALZHEIMER'S DISEASE
Source text for Eikon: ID:nWkr4SprpZ
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln